The cheap tub of creatine monohydrate in your cupboard just lost a head-to-head trial to its pricier, trendier cousins. But before you reorder, read the fine print: this study has real limits, and the result runs against earlier research.
What the researchers actually tested
A team from the Sports Science Department at Wenzhou Medical University in China, led by Duan, published a randomized, placebo-controlled trial in the Journal of the International Society of Sports Nutrition in 2026. They recruited 40 male collegiate soccer players and split them into four parallel groups of 10:
- Creatine monohydrate (Cr-Mon)
- Creatine ethyl ester (Cr-Ee)
- Creatine hydrochloride (Cr-HCl)
- Placebo
Everyone completed the same 4-week preparatory phase of repeated sprint training, three sessions a week for 12 sessions in total. Before and after, the players were tested on countermovement vertical jump (CMVJ), 20-m sprint, an L-run agility test, a Wingate anaerobic power test (peak power, mean power and fatigue index) and an incremental test for VO2max.
The headline result: the "fancy" forms pulled ahead
First, the unsurprising part. Every group improved, including placebo, which is what you would expect from a month of structured sprint work. The creatine groups, however, improved significantly more than placebo in physical performance, peak power output and fatigue index (reported at p = 0.001).
Then came the twist. According to the abstract, the ethyl ester and HCl forms produced superior gains (p < 0.05) in physical performance and peak power compared with monohydrate. The authors specifically highlight the CMVJ, 20-m sprint, L-run and peak power as the areas where Cr-Ee and Cr-HCl added the extra edge.
So in this trial, the premium-priced and heavily marketed forms did not just match monohydrate. They beat it on the explosive, short-burst measures that matter most for soccer.
Where the forms did NOT differ
Not everything split along formulation lines. The abstract reports no significant differences among the groups for mean power output or VO2max. That fits the usual picture of creatine as a short-burst, high-intensity aid. It supports phosphocreatine-dependent efforts like sprints and jumps, rather than aerobic capacity.
Why you shouldn't ditch monohydrate yet
This is where an honest read matters more than a clickable one.
The groups were tiny. With only 10 athletes per arm, a few unusually responsive players could swing the group averages. Small trials are good at generating hypotheses and poor at settling debates.
Four weeks is short. Nothing here speaks to longer-term performance, health markers or how the forms compare over a full season.
The sample is narrow. All participants were young, male, collegiate soccer players. The results may not carry over to women, older adults, other sports or people who do not train.
The abstract does not report muscle creatine. Without direct measures of muscle creatine content, we cannot tell whether the newer forms actually raised creatine stores more or whether something else explains the gap. The abstract also does not give the dose used for each form, so we cannot say whether the groups were matched by creatine content, and we should not assume they were.
It contradicts earlier work. A well-known 2009 study by Spillane and colleagues found that creatine ethyl ester was no better than monohydrate for body composition and performance, and that it was associated with higher serum creatinine. One new trial does not erase that, and the two findings are hard to reconcile without more data.
Monohydrate still has the evidence advantage. It is the most researched creatine form, widely available and typically the cheapest. A form can beat it in one small trial and still not be the better buy.
The authors report no conflicts of interest, which is reassuring, but it does not fix the design constraints.
Practical takeaways
Dose: The abstract does not state the dose for each form, so do not copy a protocol from this paper. If you use monohydrate, follow the dosing on a reputable product label or the guidance of a qualified sports dietitian. If you try HCl, follow that product's label.
Timing: The study design was daily supplementation across a 4-week training block alongside repeated sprint training, three sessions a week. The abstract does not say when during the day it was taken, and creatine's effect depends more on consistent use than on a precise hour.
Who it may suit: Field and court athletes building sprint, jump and agility capacity, especially in a preseason block. Those who find monohydrate hard on the stomach might reasonably explore HCl, though this study did not test tolerability, so that is a practical consideration rather than a finding.
Who should be cautious or skip it: People with kidney disease or other medical conditions, those taking medications, and anyone under 18 should speak with a doctor first. Ethyl ester deserves extra caution given the earlier creatinine finding. Anyone who is happy and getting results on monohydrate has no strong reason to switch on this evidence alone.
Bottom line
This trial is a genuinely interesting signal that creatine HCl and ethyl ester may offer an edge for jumps, sprints, agility and peak power over a short training block. But 40 athletes, 4 weeks and a missing dose breakdown make it a prompt for further research, not a reason to bin your monohydrate. Until larger, longer trials with muscle creatine measurements confirm it, monohydrate remains the proven, affordable default, and HCl is the intriguing challenger to watch.
